Rosuvastatin Calcium (Crestor)

A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES.

Also Known As:

Networked: 2022 relevant articles (281 outcomes, 795 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Ridker, Paul M: 38 articles (12/2017 - 08/2003)
2.	Kjekshus, John: 32 articles (01/2021 - 10/2005)
3.	Wikstrand, John: 29 articles (05/2017 - 10/2005)
4.	Raichlen, Joel S: 27 articles (11/2018 - 05/2004)
5.	Ballantyne, Christie M: 27 articles (08/2017 - 01/2003)
6.	McMurray, John J V: 25 articles (01/2017 - 11/2007)
7.	Stein, Evan A: 24 articles (01/2018 - 02/2002)
8.	Nicholls, Stephen J: 22 articles (11/2019 - 04/2006)
9.	Elisaf, Moses S: 22 articles (05/2015 - 09/2005)
10.	Glynn, Robert J: 21 articles (01/2016 - 11/2008)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 01/01/2017 - "Rosuvastatin markedly improved atherogenic dyslipidemia of MS." 10/01/2009 - "Rosuvastatin has been reported to be beneficial in the treatment of dyslipidemia. " 11/19/2023 - "These findings underscore the potential of RSV-FDFs as a promising alternative to enhance the bioavailability and therapeutic efficacy of rosuvastatin in treating dyslipidemia. " 11/01/2012 - "In this study, we assessed the efficacy of rosuvastatin in NASH patients with dyslipidemia. " 02/01/2009 - "To compare the efficacy of administering rosuvastatin on a daily basis versus on an alternate day basis for the treatment of dyslipidemia. "
2.	Hypercholesterolemia 07/15/2004 - "Thus, our findings suggest that treatment with rosuvastatin in patients with hypercholesterolemia may lead to a significant reduction in plasma ADMA levels, which appear to be related to the improvement in endothelial function by rosuvastatin." 11/01/2007 - "In conclusion, long-term treatment with rosuvastatin 40 mg is safe and effective in patients with severe hypercholesterolemia." 08/01/2013 - "This study examined whether the ABCG2 421C>A polymorphism and variants in other genes potentially related to the pharmacokinetics of rosuvastatin influenced the plasma concentration of rosuvastatin in Chinese patients with hypercholesterolemia. " 01/01/2011 - "Published studies randomized trials with rosuvastatin treatment for at least 4 weeks in hypercholesterolemia patients were used for model building and validation. " 03/01/2008 - "Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study."
3.	Atherosclerosis 04/01/2010 - "This subgroup analysis of the METEOR study showed that in middle-aged adults with sub-clinical atherosclerosis, rosuvastatin treatment resulted in significant reduction in mean maximum CIMT progression in four quartiles of baseline CIMT, with no evidence for difference in benefit across levels of baseline CIMT." 10/01/2022 - "This randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. " 01/01/2021 - "Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial." 11/11/2020 - "The current METEOR-China study is designed to evaluate the effect of rosuvastatin 20 mg daily versus placebo on the progression of atherosclerosis measured by CIMT in asymptomatic Chinese subjects. " 11/11/2020 - "Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study."
4.	Type 2 Diabetes Mellitus (MODY) 10/01/2004 - "A review of the efficacy of rosuvastatin in patients with type 2 diabetes." 12/01/2016 - "This study would be the first to demonstrate the impact of rosuvastatin on the density score of coronary artery calcification in CAD patients with type 2 diabetes. " 06/01/2009 - "We performed a randomized double-blind cross-over trial of 6-week treatment period with placebo or rosuvastatin 20 mg in eight patients with type 2 diabetes. " 11/09/2017 - "These results suggest that rosuvastatin improves the postprandial cardiometabolic milieu in type 2 diabetes. " 01/25/2010 - "We compared the neurophysiological and vascular responses of dietary control and treatment with 10 mg of rosuvastatin in 16 subjects with neuropathy and established type 2 diabetes. "
5.	Inflammation (Inflammations) 04/01/2014 - "Rosuvastatin also reduced cardiac inflammation and oxidative tissue damage, reduced epididymal fat mass, and improved adipose tissue lipolysis much more in the CRP-transgenic strain than in the nontransgenic strain. " 12/01/2017 - "In 2009 the JUPITER trial demonstrated that rosuvastatin may be effective when dealing with vascular inflammation by providing an anti-inflammatory effect. " 07/01/2014 - "The present study demonstrates that rosuvastatin pretreatment ameliorates EBI after SAH through the attenuation of oxidative stress and NF-κB-mediated inflammation." 01/01/2014 - "This study was aimed to investigate the usefulness of (18)F-FDG-PET to differentiate vascular inflammation and to determine the effect of rosuvastatin. " 07/19/2012 - "In this study, we tested the hypothesis that chronic exposure to NP will aggravate AD-induced CKD through increasing generations of inflammation, ROS, and apoptosis that could be attenuated by rosuvastatin. "

Related Drugs and Biologics

1.	Atorvastatin (Lipitor)
2.	Lipids
3.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
4.	Ezetimibe (Zetia)
5.	Simvastatin (Zocor)
6.	LDL Cholesterol
7.	oxidized low density lipoprotein
8.	C-Reactive Protein
9.	Cholesterol
10.	Pravastatin (Pravachol)

Related Therapies and Procedures

1.	Therapeutics
2.	Percutaneous Coronary Intervention
3.	Stents
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Highly Active Antiretroviral Therapy (HAART)